Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Mycosis Fungoides Market Set to Expand by 2034 with Advancements in Targeted and Immunotherapy Approaches | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Nov 26, 2025, 17:31 ET

      Share this article

      Share this article


      The mycosis fungoides market is anticipated to progress steadily, influenced by the relatively small pipeline of emerging therapies. Leading candidates such as Soligenix's HYBRYTE and Innate Pharma's Lacutamab, among others, reflect a strong industry commitment to meeting this unmet medical need through the continued development of innovative treatments for this challenging disease.

      LAS VEGAS, Nov. 26, 2025 /PRNewswire/ -- DelveInsight's Mycosis Fungoides Market Insights report includes a comprehensive understanding of current treatment practices, mycosis fungoides emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). 

      Mycosis Fungoides Market Summary

      • The market size for mycosis fungoides in the leading markets is expected to grow significantly by 2034.
      • The United States accounted for the highest mycosis fungoides treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
      • Mycosis fungoides is rare in individuals under 40 and occurs about twice as frequently in men as in women.
      • Leading mycosis fungoides companies developing emerging therapies, such as Soligenix, Innate Pharma, SciTech Development, Prescient Therapeutics, and others, are developing new therapy for mycosis fungoides that can be available in the mycosis fungoides market in the coming years. 
      • The promising mycosis fungoides therapies in clinical trials include HYBRYTE (Hypericin), Lacutamab (IPH4102), Fenretinide, PTX-100, and others.

      Discover the mycosis fungoides new treatment @ New Treatments for Mycosis Fungoides

      Key Factors Driving the Growth of the Mycosis Fungoides Market 

      Increasing Prevalence of Mycosis Fungoides

      The mycosis fungoides market is expanding due to a rising number of mycosis fungoides cases, which is the most common type of cutaneous T-cell lymphoma. Studies have shown a steady increase in the incidence of this condition over time.

      Advancements in Treatment Options

      Significant progress in therapeutic options is a major catalyst for market growth. These advancements encompass a range of treatments, from innovative systemic therapies to improved skin-directed treatments.

      Launch of Emerging Mycosis Fungoides Therapies

      The anticipated launch of emerging therapies such as HYBRYTE (Soligenix), Lacutamab (Innate Pharma), Fenretinide (SciTech Development), PTX-100 (Prescient Therapeutics), and others will propel the mycosis fungoides market.

      Mycosis Fungoides Market Analysis

      The mycosis fungoides market is projected to experience consistent growth from 2025 to 2034, fueled by increasing disease awareness, earlier detection, and the availability of established treatment options. Ongoing advancements in targeted therapies, immunotherapies, and a robust research pipeline are expected to drive market expansion further.

      Key targeted therapies include POTELIGEO (mogamulizumab-kpkc) by Kyowa Kirin and ADCETRIS (brentuximab vedotin) by Pfizer, both offering disease-specific mechanisms that enhance outcomes in relapsed or refractory mycosis fungoides.

      Emerging candidates, such as HYBRYTE (Soligenix) and Lacutamab (Innate Pharma), are also advancing their clinical development. HYBRYTE leverages topical photodynamic therapy with synthetic hypericin, while Lacutamab introduces a first-in-class anti-KIR3DL2 monoclonal antibody, addressing unmet therapeutic needs in both early-stage and relapsed/refractory disease settings.

      To know more about mycosis fungoides treatment options, visit @ Approved Mycosis Fungoides Drugs

      Mycosis Fungoides Competitive Landscape

      Some of the mycosis fungoides drugs in clinical trials include HYBRYTE (Soligenix), Lacutamab (Innate Pharma), Fenretinide (SciTech Development), PTX-100 (Prescient Therapeutics), and others.

      Soligenix's HYBRYTE is a novel, first-in-class photodynamic therapy designed to treat mycosis fungoides. It employs synthetic hypericin, a topical photosensitizer selectively absorbed by malignant T-cells and activated by safe, visible red-yellow light after 24 hours. This wavelength penetrates more deeply than ultraviolet light, allowing effective treatment of thicker lesions while minimizing the risk of UV-induced secondary cancers. The therapy has been granted orphan drug and fast track designations by the FDA and orphan designation by the European Medicines Agency (EMA).

      Innate Pharma's Lacutamab (IPH4102) is a pioneering humanized antibody targeting KIR3DL2, designed to induce cytotoxicity in malignant T-cells. It is under clinical evaluation for cutaneous T-cell lymphoma (CTCL), a rare group of T-lymphocyte malignancies with poor prognosis and limited treatment options in advanced stages. The drug is currently in Phase II development for mycosis fungoides.

      Innate Pharma shared updated findings from the TELLOMAK Phase II trial, including long-term follow-up and translational data, on Lacutamab in relapsed and/or refractory mycosis fungoides at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (May 30–June 3, 2025).

      The anticipated launch of these emerging therapies are poised to transform the mycosis fungoides market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the mycosis fungoides market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about therapy for mycosis fungoides @ Mycosis Fungoides Clinical Trials 

      What is Mycosis Fungoides?

      Mycosis fungoides is a type of cutaneous T-cell lymphoma that typically progresses slowly and chronically. It is characterized by the accumulation of lymphocytes in the skin, leading to the development of plaques and nodular lesions. In advanced cases, ulcerating tumors may develop, and malignant cells can spread to the lymph nodes. The disease may also extend beyond the skin, involving internal organs such as the liver, spleen, gastrointestinal tract, or central nervous system.

      The condition generally evolves through three stages: patch, plaque, and tumor. The patch stage appears as flat, reddish areas, while the plaque stage is characterized by raised, reddish-brown or grayish lesions. These two represent the early phases of the disease. In the tumor stage, large, irregular lumps emerge, originating from existing plaques or normal skin, and can appear anywhere on the body, including the face and scalp.

      Mycosis Fungoides Epidemiology Segmentation

      The mycosis fungoides epidemiology section provides insights into the historical and current mycosis fungoides patient pool and forecasted trends for the leading markets. In Europe and the United States, mycosis fungoides occurs at a rate of about 6 cases per million people annually, representing roughly 4% of all non-Hodgkin lymphomas. It is seen more frequently in individuals over the age of 50.

      The mycosis fungoides market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

      • Incident Cases of Mycosis Fungoides 
      • Age-specific Cases of Mycosis Fungoides
      • Gender-specific Cases of Mycosis Fungoides
      • Type-specific Cases of Mycosis Fungoides 
      • Treated Cases of Mycosis Fungoides

      Mycosis Fungoides Market Report Metrics

      Details

      Study Period

      2020–2034

      Mycosis Fungoides Market Report Coverage

      7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Mycosis Fungoides Epidemiology Segmentation

      Incident Cases of Mycosis Fungoides, Age-specific Cases of Mycosis Fungoides, Gender-specific Cases of Mycosis Fungoides, Type-specific Cases of Mycosis Fungoides, and Treated Cases of Mycosis Fungoides

      Key Mycosis Fungoides Companies

      Soligenix, Innate Pharma, SciTech Development, Prescient Therapeutics, Kyowa Kirin, Pfizer, and others

      Key Mycosis Fungoides Therapies

      HYBRYTE (Hypericin), Lacutamab (IPH4102), Fenretinide, PTX-100, POTELIGEO, ADCETRIS, and others

      Scope of the Mycosis Fungoides Market Report

      • Therapeutic Assessment: Mycosis Fungoides current marketed and emerging therapies
      • Mycosis Fungoides Market Dynamics: Key Market Forecast Assumptions of Emerging Mycosis Fungoides Drugs and Market Outlook
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, Mycosis Fungoides Market Access and Reimbursement

      Download the report to understand which factors are driving mycosis fungoides therapeutics market trends @ Mycosis Fungoides Market Trends

      Table of Contents

      1

      Mycosis Fungoides Market Key Insights

      2

      Mycosis Fungoides Market Report Introduction 

      3

      Mycosis Fungoides Market Overview at a Glance

      3.1

      Mycosis Fungoides Market Share (%) Distribution by Therapies in 2024

      3.2

      Mycosis Fungoides Market Share (%) Distribution by Therapies in 2034

      4

      Epidemiology and Market Methodology 

      5

      Executive Summary

      6

      Key Events

      7

      Disease Background and Overview

      7.1

      Introduction

      7.2

      Mycosis Fungoides Types

      7.3

      Mycosis Fungoides Causes

      7.4

      Mycosis Fungoides Pathophysiology

      7.5

      Mycosis Fungoides Symptoms

      7.6

      Mycosis Fungoides Risk Factor

      7.7

      Mycosis Fungoides Diagnosis

      7.8

      Mycosis Fungoides Treatment and Management

      8

      Epidemiology and Patient Population

      8.1

      Key Findings

      8.2

      Assumptions and Rationale: The 7MM

      8.3

      Incident Cases of Mycosis Fungoides in the 7MM

      8.4

      The United States

      8.4.1

      Incident Cases of Mycosis Fungoides

      8.4.2

      Age-specific Cases of Mycosis Fungoides 

      8.4.3

      Gender-specific Cases of Mycosis Fungoides 

      8.4.4

      Type-specific Cases of Mycosis Fungoides

      8.4.5

      Treated Cases of Mycosis Fungoides 

      8.5

      EU4 and the UK

      8.6

      Japan

      9

      Mycosis Fungoides Patient Journey

      10

      Marketed Mycosis Fungoides Therapies

      10.1

      Key Cross Competition

      10.2

      POTELIGEO (mogamulizumab-kpkc): Kyowa Kirin

      10.2.1

      Drug Description

      10.2.2

      Regulatory Milestones

      10.2.3

      Other Development Activities

      10.2.4

      Clinical Trials Information

      10.2.5

      Safety and Efficacy

      10.3

      ADCETRIS (brentuximab vedotin): Pfizer

      To be continued in the report….

      11

      Emerging Mycosis Fungoides Therapies

      11.1

      Key Cross Competition

      11.2

      HYBRYTE (Hypericin): Soligenix

      11.2.1

      Drug Description

      11.2.2

      Other Development Activities

      11.2.3

      Clinical Trials Information

      11.2.4

      Safety and Efficacy

      11.2.5

      Analysts' Views

      11.3

      Lacutamab (IPH4102): Innate Pharma

      To be continued in the report….

      12

      Mycosis Fungoides Market: Seven Major Market Analysis

      12.1

      Key Findings

      12.2

      Key Mycosis Fungoides Market Forecast Assumptions

      12.3

      Mycosis Fungoides Market Outlook

      12.4

      Attribute Analysis

      12.5

      Total Market Size of Mycosis Fungoides in the 7MM

      12.6

      Market Size of Mycosis Fungoides by Therapies in the 7MM

      12.7

      The United States Mycosis Fungoides Market Size

      12.7.1

      Total Market Size of Mycosis Fungoides

      12.7.2

      Market Size of Mycosis Fungoides by Therapies

      12.8

      EU4 and the UK Mycosis Fungoides Market Size

      12.9.

      Japan Mycosis Fungoides Market Size

      13

      Key Opinion Leaders' Views on Mycosis Fungoides 

      14

      Mycosis Fungoides Market Unmet Needs

      15

      Mycosis Fungoides Market SWOT Analysis

      16

      Mycosis Fungoides Market Access and Reimbursement

      16.1

      United States

      16.2

      EU4 and the UK

      16.3

      Japan

      17

      Bibliography

      18

      Abbreviations and Acronyms

      19

      Mycosis Fungoides Market Report Methodology

      Related Reports

      Mycosis Fungoides Clinical Trial Analysis

      Mycosis Fungoides Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mycosis fungoides companies, including Innate Pharma, Soligenix, Bristol-Myers Squibb, among others.

      Cutaneous T-cell Lymphoma Market

      Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTCL companies, including Soligenix and Sterling Pharma Solutions, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, ONO Pharmaceutical, among others.

      Non-Hodgkin's Lymphoma Market

      Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-Hodgkin's lymphoma companies, including Soligenix, Innate Pharma, Nurix Therapeutics, AstraZeneca, Merck, Prescient Therapeutics, Kite Pharma, Seagen, Takeda, Novartis, Daiichi Sankyo, Genmab, AbbVie, Genentech (a Member of Roche), Bristol Myers Squibb, among others.

      Hodgkin's Lymphoma Market

      Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Hodgkin's lymphoma companies, including Merck, BeiGene, Tessa Therapeutics, Genmab, Bristol-Myers Squibb, AstraZeneca, Pfizer, Takeda, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur
      [email protected]
      +14699457679
      www.delveinsight.com 

      Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.